文献速递心脑血管急症重症综合管理与镇静镇痛

心肌梗死后射血分数保留患者的β受体阻滞剂治疗

Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
PubMed 文献 · N Engl J Med · 2024-04-07
一句话结论急性心梗、LVEF≥50%且行早期冠脉造影者,长期用β受体阻滞剂未降低全因死亡或新发心梗复合终点风险(HR 0.96,95%CI 0.79–1.16,P=0.64)。

REDUCE-AMI研究在瑞典、爱沙尼亚、新西兰45个中心纳入5020例急性心梗、已行冠脉造影且LVEF≥50%的患者,随机接受长期β受体阻滞剂(美托洛尔或比索洛尔)或不使用β受体阻滞剂。中位随访3.5年,主要终点(全因死亡或新发心梗)在β受体阻滞剂组7.9%、无β受体阻滞剂组8.3%(HR 0.96;95%CI 0.79–1.16;P=0.64)。次要终点及安全性终点两组均无显著差异。结论:LVEF保留的急性心梗患者长期β受体阻滞剂未降低主要复合终点风险。

要点

  • 急性心梗、行冠脉造影且LVEF≥50%者,长期β受体阻滞剂主要终点事件7.9% vs 无β受体阻滞剂8.3%(HR 0.96;95%CI 0.79–1.16;P=0.64)。
  • 全因死亡β受体阻滞剂组3.9% vs 无β受体阻滞剂组4.1%,心血管死亡1.5% vs 1.3%,心梗4.5% vs 4.7%。
  • 因房颤住院1.1% vs 1.4%,因心衰住院0.8% vs 0.9%,两组次要终点均未见β受体阻滞剂获益。
  • 安全性终点:心动过缓、二度或三度房室传导阻滞、低血压、晕厥或起搏器植入3.4% vs 3.2%;哮喘或慢阻肺住院0.6% vs 0.6%;卒中住院1.4% vs 1.8%。
  • 研究于2017年9月至2023年5月入组5020例(95.4%来自瑞典),中位随访3.5年(四分位距2.2–4.7年)。

适用人群与场景

  • 急性心肌梗死、已行冠状动脉造影且左心室射血分数至少50%的患者。
  • 研究在瑞典、爱沙尼亚和新西兰的45个中心进行,95.4%的患者来自瑞典。

诊断标准与关键阈值

  • 左心室射血分数至少50%(射血分数保留)。

处置流程与药物剂量

  • β受体阻滞剂组接受长期美托洛尔或比索洛尔治疗;对照组不接受β受体阻滞剂治疗。

研究设计与关键结果

  • 平行组、开放标签试验,45个中心,纳入5020例急性心梗、已行冠脉造影且LVEF≥50%的患者,随机接受长期β受体阻滞剂(美托洛尔或比索洛尔)或不使用β受体阻滞剂。
  • 主要终点(全因死亡或新发心梗复合终点):β受体阻滞剂组199/2508例(7.9%)vs 无β受体阻滞剂组208/2512例(8.3%),HR 0.96(95%CI 0.79–1.16),P=0.64。
  • 全因死亡:β受体阻滞剂组3.9% vs 无β受体阻滞剂组4.1%;心血管死亡:1.5% vs 1.3%;心肌梗死:4.5% vs 4.7%;因房颤住院:1.1% vs 1.4%;因心衰住院:0.8% vs 0.9%。
  • 安全性终点:因心动过缓、二度或三度房室传导阻滞、低血压、晕厥或起搏器植入住院:β受体阻滞剂组3.4% vs 无β受体阻滞剂组3.2%;因哮喘或慢阻肺住院:0.6% vs 0.6%;因卒中住院:1.4% vs 1.8%。
  • 中位随访3.5年(四分位距2.2–4.7年);入组时间2017年9月至2023年5月。

证据类型、等级与局限

  • 研究类型:平行组、开放标签随机对照试验(REDUCE-AMI,ClinicalTrials.gov NCT03278509)。
  • 资助:瑞典研究委员会等。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急性心梗、行早期冠脉造影且LVEF≥50%的患者,长期β受体阻滞剂治疗未较不使用β受体阻滞剂降低全因死亡或新发心梗复合终点风险(HR 0.96;95%CI 0.79–1.16;P=0.64)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin-angiotensin-aldosterone system antagonists.

METHODS: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients with an acute myocardial infarction who had undergone coronary angiography and had a left ventricular ejection fraction of at least 50% to receive either long-term treatment with a beta-blocker (metoprolol or bisoprolol) or no beta-blocker treatment. The primary end point was a composite of death from any cause or new myocardial infarction.

RESULTS: From September 2017 through May 2023, a total of 5020 patients were enrolled (95.4% of whom were from Sweden). The median follow-up was 3.5 years (interquartile range, 2.2 to 4.7). A primary end-point event occurred in 199 of 2508 patients (7.9%) in the beta-blocker group and in 208 of 2512 patients (8.3%) in the no-beta-blocker group (hazard ratio, 0.96; 95% confidence interval, 0.79 to 1.16; P = 0.64). Beta-blocker treatment did not appear to lead to a lower cumulative incidence of the secondary end points (death from any cause, 3.9% in the beta-blocker group and 4.1% in the no-beta-blocker group; death from cardiovascular causes, 1.5% and 1.3%, respectively; myocardial infarction, 4.5% and 4.7%; hospitalization for atrial fibrillation, 1.1% and 1.4%; and hospitalization for heart failure, 0.8% and 0.9%). With regard to safety end points, hospitalization for bradycardia, second- or third-degree atrioventricular block, hypotension, syncope, or implantation of a pacemaker occurred in 3.4% of the patients in the beta-blocker group and in 3.2% of those in the no-beta-blocker group; hospitalization for asthma or chronic obstructive pulmonary disease in 0.6% and 0.6%, respectively; and hospitalization for stroke in 1.4% and 1.8%.

CONCLUSIONS: Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker treatment did not lead to a lower risk of the composite primary end point of death from any cause or new myocardial infarction than no beta-blocker use. (Funded by the Swedish Research Council and others; REDUCE-AMI ClinicalTrials.gov number, NCT03278509.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024. PMID: 38587241. doi:10.1056/NEJMoa2401479

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。